Abstract:Huntington's disease (HD) and Spinocerebellar ataxia type I (SCA1) are two of a class of dominant, neurodegenerative diseases caused by a polyglutamine (polyQ) expansion. The mutation confers a toxic gain of function to the protein, with polyQ length predictive of age of onset and disease severity. There is no curative or preventative therapy for HD or SCA1, supporting the investigation of novel strategies. In other work, we showed that gene silencing by RNA interference (RNAi) can be achieved in vitro and in vivo by expressing short hairpin RNAs (shRNAs) specific for mRNAs encoding ataxin-1 or huntingtin. Currently, strong, constitutive polIII promoters (U6 and H1) are used to express shRNAs, which are subsequently processed into functional small interfering RNAs (siRNAs). However, strong, constitutive expression of shRNAs may be inappropriate for diseases that take several decades to manifest. Moreover, high-level expression may be unnecessary for sustained benefit, and in some systems may induce a non-specific interferon response leading to global shut-down of gene expression. We therefore investigated the use of polII-expressed microRNAs (miRNAs) as siRNA shuttles as an alternative strategy. Due to their endogenous nature, miRNA backbones may prevent the induction of the interferon response. Using human mir-30 as a template, we designed miRNA shuttles that upon processing by dicer would release siRNAs specific for ataxin-1. Constructs containing polII-expressed miRNA shuttles with embedded ataxin-1-specific siRNAs were co-transfected into cells with GFP-tagged ataxin-1, and gene silencing was assessed by fluorescence microscopy and western analysis. We observed dramatic and dose-dependent gene silencing relative to non-specific miRNAs carrying control siRNAs. This polII-based expression system exploits the structure of known miRNAs and supports tissue-specific as well as inducible siRNA expression, and thus, serves as a unique and powerful alternative to dominant neurodegenerative disease therapy by RNAi.

Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model

Cyclodextrin-Based Nanoparticles for Delivery of Antisense Oligonucleotides Targeting Huntingtin

Therapeutic Reversal of Huntington’s Disease by in Vivo Self-Assembled Sirnas

Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease

I02 Systemic Injection of Exosomal Sirna Significantly Reduced Huntingtin Expression in Transgenic Mice of Huntington’s Disease

Efficient delivery of siRNA to cortical neurons using layered double hydroxide nanoparticles.

mRNA nuclear clustering leads to a difference in mutant huntingtin mRNA and protein silencing by siRNAs

Progress in studies of gene therapy for Huntington's disease

mRNA Nuclear Clustering Leads to a Difference in Mutant Huntingtin mRNA and Protein Silencing by siRNAs In Vivo

Nonviral siRNA delivery for gene silencing in neurodegenerative diseases

RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA

207. Micro RNAs as Novel siRNA Shuttles

Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi

An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington’s disease models

Engineered chitosan-derived nanocarrier for efficient siRNA delivery to peripheral and central neurons

Sequencing-Guided Design of Genetically Encoded Small RNAs Targeting CAG Repeats for Selective Inhibition of Mutant Huntingtin

A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system

Delivery of Small Interfering RNA by Hydrogen Sulfide-Releasing Nanomotor for the Treatment of Parkinson's Disease

RVG-peptide-linked trimethylated chitosan for delivery of siRNA to the brain.

An insight into allele-selective approaches to lowering mutant huntingtin protein for Huntington's disease treatment

Latest Advances on New Promising Molecular-Based Therapeutic Approaches for Huntington’s Disease